Finance O, Manning A, Chatelain P
Department of Pharmacology, Sanofi Research, Brussels, Belgium.
J Cardiovasc Pharmacol. 1995 Oct;26(4):570-6. doi: 10.1097/00005344-199510000-00010.
We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs. Ischemia was induced by occlusion of the left coronary descending artery (LAD) for 30 min. Premature ventricular complexes (PVCs), ventricular tachycardia (VT), and ventricular fibrillation (VF) were recorded during coronary occlusion. SR 33589 (1.25, 2.50, and 5 mg/kg intravenously, i.v.) markedly reduced the occurrence of ventricular arrhythmias during ischemia. The incidence of VF was reduced from 90% in the control group to 30% (p < 0.05) with 1.25 mg/kg, to 10% (p < 0.001) with 2.50 mg/kg, and to 20% (p < 0.01) with 5 mg/kg. In addition, SR 33589, especially at the two higher doses, caused a sustained reduction in both the incidence of VT and the number of PVCs per minute. In comparison, amiodarone 10 and 20 mg/kg i.v. reduced the incidence of VF (40 and 50%, respectively), but these reductions never reached a level of statistical significance. The incidence of VT and the number of PVCs per minute were also decreased significantly by amiodarone. D,L-sotalol 3 mg/kg i.v. exerted significant anti-arrhythmic activity; the incidence of VF was reduced 20% (p < 0.01), and both the incidence of VT and number of PVC per minute were also reduced. In contrast, lignocaine given as a 2-mg/kg bolus followed by an infusion at 70 micrograms/kg/min had no antiarrhythmic or antifibrillatory activity in this preparation.(ABSTRACT TRUNCATED AT 250 WORDS)
我们比较了一种新型胺碘酮样药物SR 33589与胺碘酮、D,L-索他洛尔和利多卡因在降低麻醉猪急性冠状动脉闭塞所致室颤(VF)及相关心律失常发生率方面的能力。通过闭塞左冠状动脉前降支(LAD)30分钟诱导缺血。在冠状动脉闭塞期间记录室性早搏(PVC)、室性心动过速(VT)和室颤(VF)。SR 33589(静脉注射1.25、2.50和5mg/kg)显著降低了缺血期间室性心律失常的发生。VF发生率从对照组的90%分别降至1.25mg/kg时的30%(p<0.05)、2.50mg/kg时的10%(p<0.001)和5mg/kg时的20%(p<0.01)。此外,SR 33589,尤其是较高的两个剂量,使VT发生率和每分钟PVC数量持续降低。相比之下,静脉注射10和20mg/kg胺碘酮降低了VF发生率(分别为40%和50%),但这些降低从未达到统计学显著水平。胺碘酮也显著降低了VT发生率和每分钟PVC数量。静脉注射3mg/kg D,L-索他洛尔具有显著的抗心律失常活性;VF发生率降低了20%(p<0.01),VT发生率和每分钟PVC数量也降低了。相比之下,在本制剂中,静脉推注2mg/kg利多卡因后以70μg/kg/min输注,没有抗心律失常或抗纤颤活性。(摘要截断于250字)